Improved progression‐free survival, increased toxicities seen with amivantamab for EGFR‐mutant NSCLC

School of Medicine in St. Louis, Missouri, says that, if approved, the perioperative regimen evaluated in the AEGEAN trial "will represent another option for perioperative therapy in NSCLC."He also underscores a key question left unanswered by both trials."The main question about AEGEAN and KEYNOTE-671 is whether the patients need the adjuvant part, particularly those who achieve a complete pathologic response."In an editorial published in October 2023 before the AEGEAN results and in response to the KEYNOTE-671 interim data, the authors laid out further questions that remain unanswered about the use of neoadjuvant and perioperative treatment for lung cancer, including whether there are patients for whom surgery can be omitted, what the optimal duration of therapy is, and what the optimal timing is for surgery after neoadjuvant immunotherapy. 4 The authors wrote that the data coming from trials such as AEGEAN and KEYNOTE-671 (among others) will have a "profound impact on the practice of thoracic surgical oncology," and they underscored that "it is paramount that thoracic surgeons remain engaged in both the standard-of-care and clinical trials settings as this paradigm evolves." 4